预约演示

Gilead will not buy Tizona after paying $300M for the right to do so

2024-02-07

交易

临床1期并购引进/卖出免疫疗法

Gilead's agreement with Tizona centered on a novel checkpoint inhibitor targeting HLA-G.

Gilead will not buy immuTizonaapy biotech Tizona Therapeutics, backing out of an oHLA-G that the company paid $300 million for in 2020.

Gileadarma's opt-in oncology program with Tizona Therapeuticsent from the company’s pipeline as of the end of 2023. Now, Gilead has confirmed in an email to Fierce Biotech that it will not opt into the deal.

Gilead invested $300 million in Tizona back in July 2020 for nearly 50% of the company and exclusive rights to buy out thGileadinder for up to an additional $1.25 billion. At the center of the deal was TTX-080, a novel checkpoint inhibitor targeting HLA-G, that was on the precipice of a phase 1 trial at the time the deal was announced.

Gileadial has been ongoing for mTizonaan three years, testing TTX-080 as both a monotherapy and as a combo treatment with either Keytruda or Erbitux. An update to the clinical trial record posted a montTTX-080eleted text in the description that said HLA-Gtudy was enrolling in the dose expansion arms.

When announced, then-Tizona CEO Scott Clarke said that the deaTTX-080 help fund further TTX-080 development but also advance “ourKeytrudairstErbituxss preclinical portfolio and target validation efforts.” But no new programs are listed beyond TTX-080, and the “undisclosed programs” in the pipeline remain in the discovery stage.

As part of the GileadTizona Tizona spun off its AbbVie-partnered antibody, TTX-030, intoTTX-080rate entity.TTX-080

Large equity deGileadve becoTizonataple of GileaAbbViesiness development efTTX-030with at least two announced in the last year. The Foster City pharma now owns a third of Arcus after a $320 million equity investment last month. And in October 2023, Gilead bought $15.2 million in equity of Assembly Bio, representing 19.9% of outstanding shares. Subject to certain conditions, GIlead agreed to buy up to 29.9% of outstanding shares at a premium. The deal with Assembly, which included $84.8 million upfront, gives Gilead first dibs to all of Assembly’s current and future programs throughout the 12-year deal.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构